

# Members Obtain Free CE Credits from JCP Articles!



## ***Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis***

February 2023 – *The Journal of Clinical Pharmacology* (JCP)

### ***Why is this article important to you?***

ASPECT-NP, a Phase 3 trial of ceftolozane/tazobactam in hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), excluded patients with end-stage renal disease (ESRD). This study utilized a modeling/simulation approach to inform optimal dosing in this population, using previously-published population pharmacokinetic (PK) models informed by clinical study data. Investigators conducted probability of target attainment simulations (PTA) in both plasma and epithelial lining fluid, for three different ceftolozane-tazobactam dosing regimens. Learners who complete this activity will be able to explain how modeling/simulation can help to inform optimal ceftolozane-tazobactam dosing and detail the steps involved when utilizing population PK models informed by clinical data.



### **ACPE Accreditation Statement**

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

**UAN: 0665-0000-23-002-H01-P**– ACPE 1 Contact Hours

**Activity Type:** Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME  
ACCREDITED

### **ACCME Accreditation Statement**

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### **ACCME Designation Statement**

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **Target Audience**

Interprofessional team of Physicians, Pharmacists and PhDs.

### **Learning Objectives**

After completing this activity, the learner will be able to:

1. Describe how a modeling/simulation approach can help inform optimal dosing in special populations;
2. Explain how PK/PD targets were chosen for ceftolozane and tazobactam in the PTA simulations;
3. Recall the dosing regimen that results in adequate PTA for patients with HABP/VABP and ESRD requiring intermittent hemodialysis.

### **Requirements to Receive Credit**

To receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed

within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact [CE@ACCP1.org](mailto:CE@ACCP1.org) with any questions.

#### **Disclosures:**

Article Selection: Joseph S. Bertino Jr, PharmD, Editor-in-Chief, *The Journal of Clinical Pharmacology*, planner for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

Planners: Jack Chang, PharmD, Pharmacotherapy Fellow, planner for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

CE Reviewer: Robert Bies, PharmD, PhD, Associate Professor, Univ of Buffalo SUNY School of Pharmacy & Pharmaceutical Sciences, reviewer for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

#### **Schedule & Fees**

JCP monthly Journal CE articles are generally released on the 1<sup>st</sup> or 2<sup>nd</sup> Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

#### **Acknowledgement of Financial Support**

No financial support was received for this educational activity.

#### **Home Study Initial Release and Expiration Dates**

**Date of Issuance:** 02/02/2023

**Expiration Date:** 02/02/2026

---

#### **System Requirements**

For best visual quality, we recommend viewing the Journal CE in the Chrome browser. If you do not have Chrome, you can download it [here](#).

#### **Helpful Tips**

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).

---